
In Search Of A Gentler Tuscany: The Story Of Ampeleia Winery
Ampeleia
From its hillside perch in the Colline Metallifere, Ampeleia Winery looks out over a patchwork of woodlands and olive groves. On early autumn mornings, fog gathers in the folds below the vineyards before lifting with the sun to reveal distant ridgelines. To anyone who has toured wineries in Tuscany, the setting rings of the Italian hinterland. The red-tiled rooftops of the medieval village of Roccatederighi, within view of the winery's terrace, a handy giveaway. Yet, Ampeleia, a biodynamic winery set in a lesser-traveled corner of Alta Maremma, doesn't operate by the region's expected playbook. Rather, it moves at the pace of its landscape: deliberate, adaptive, and closely attuned to its environment.
Ampeleia's story begins not with a winery, but with an idea of rural life. In the 1960s, Swiss couple Erica and Peter Max Suter arrived in the hills above the village and purchased a span of abandoned land. They raised sheep and pigeons, and planted the estate's first vines, including Cabernet Franc and Merlot, long before those varieties had gained traction in the area.
The estate started a new chapter in the early aughts when Elisabetta Foradori, Thomas Widmann, and Giovanni Podini acquired the property and renamed it Ampeleia. Foradori, well-known for her natural and sustainable winemaking in Alto Adige, notably with Teroldego, lent her brand of minimalism and experimentation to the project's cache.
The terrace at Ampeleia Winery.
Ampeleia Winery
Seeing potential in Maremma's lesser-known mountains, the trio sought to create a model for thoughtful farming and expressive winemaking. In 2009, the group began the meticulous work of converting their largest vineyard holdings from organic to biodynamic farming, an effort that has since expanded to include nearly the entire estate.
Today, the Podini family remain stewards of the property with Podini at the helm and Foradori serving on the board. Winemaker Marco Tait runs the cellar and calls his approach to crafting wines one of both "rigor and intuition,' which parallels their relationship with the land, which he calls both 'humble and ambitious."
From the beginning, the mission was clear: to farm in a way that respected the land's complexity and create wines that spoke transparently about their origin. Tait attributes the decision to convert to biodynamics as one of practicality rather than ideology: "Biodynamics is not a philosophy for us, it's a method. Healthy soils yield vibrant vines, and vibrant vines make wines with life."
The nearby medieval village of Roccatederighi.
Ampeleia Winery
While the estate comprises nearly 300 acres, only 86 are planted with vines. The remainder serves the flora and fauna, as well as the needs of biodynamic winegrowing through forest, pasture, and farmland. Ampeleia's location within the Colline Metallifere, a region once shaped by the mining industry, now recognized as a UNESCO Geopark, translates to mineral-rich soil. This lends a a distinct clarity to otherwise unfiltered wines.
Terroir spans more than soil, however, and within Ampeleia's vineyards, altitude, slope, and aspect shift dramatically. The rumpled topography creates a range of microclimates and expressions.
"Some vineyards express themselves best on their own, others when blended from the start," says Francesco Pascucci, the winery's export manager. "Each vintage teaches us something new."
Sustainability efforts extend beyond the vineyard. The winery uses gravity flow in the cellar to reduce energy consumption, the viticulture team plants cover crops betweeen vines, and the entire operation runs largely on solar panels. "It's about always asking how we can do better—not just in the vineyard, but in packaging, water use, shipments, everything," says marketing manager Maria Giulia Songini.
As for its wines? Cabernet Franc has become central to Ampeleia's identity, not by strategic design but through accumulated experience. "We recognized its potential early," says Tait. "It gives us layers of nuance and lets us understand how different soils shape its voice." In 2025, two single-vineyard Cabernet Francs will be released, each from a specific set of rows selected for their distinctive character.
The summer garden thrives, providing ingredients for the agritourism offer.
Ampeleia Winery
Another key grape is Alicante Nero, which has grown in Maremma since the 1500s but was long overshadowed by higher-yielding varieties. The grape thrives in the region's Mediterranean climate, offering ripe fruit, bright acidity, and subtle spice.
In the cellar, Tait gives his wines the oversight of a custodian. Fermentations begin spontaneously. Aging takes place primarily in concrete tanks. Some wines see a technqiue called infusion, where whole clusters float in the fermenting juice, releasing aroma and giving structure without force. The resulting wines are layered and expressive.
Though rooted in Tuscany, Ampeleia's voice is distinct from regional tropes. "We are deeply Tuscan, but always in our own way," says Pascucci. That same ethos shapes their work abroad. Rather than adapting their wines to perceived market expectations, the team focuses on storytelling.
Songini notes that Unlitro, their one-liter red blend, resonates in the U.S. because it suits a relaxed, convivial setting, whether between friends on an afternoon outing or for a family-style meal at night. "It's not about marketing. It's about sharing," says Songini.
Hospitality has become an extension of this philosophy. The tasting room team welcomes visitors for seated lunches and dinners, casual bites, and wine flights or glasses on the terrace. There are several hospality experiences including a cooking class that teaches guests how to make fresh pasta and other dishes with seasonal ingredients from the garden. The tasting room sells organic soaps, olive oil, and other local, handmade products.
These newer agritourism and slow-travel experiences invite guests to understand wine not just as a product, but as a medium for connection to time, place, and each other. "We don't offer tastings so much as conversations," Songini explains. "We want people to leave with a sense of why we do what we do."
Making fresh pasta for the onsite restaurant and cooking classes.
Ampeleia Winery
Asked about the future, Tait says his winemaking will focus on refining the current portfolio rather than expanding it. Songini says they want 'to go deeper, not wider."
In a region known for bold and showy gestures, this small winery offers something quieter — a gentler side to Tuscany that wine lovers in search of characterful restraint increasingly appreciate.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company. Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings. Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris. He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School. Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership. Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented: 'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.' Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said: 'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.' ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé Contact Media France: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 Contact Media US:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments EN_2508_20_CFO_vf EN_2508_20_CFO_vf


Newsweek
an hour ago
- Newsweek
Olive Garden Launches Major Menu Update
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Olive Garden is launching a new menu offering, and for a limited time, guests will be able to score a Never Ending Pasta Bowl. The deal goes live on Monday, August 25, when the Never Ending Pasta Bowl returns at the same price of $13.99. Why It Matters As restaurants face higher costs and consumers reel in spending, brands that are able to keep prices low or offer seasonal deals and new menu items for guests may benefit financially. The exterior of an Olive Garden is seen on June 20, 2025 in Austin, Texas. Darden Restaurants, the parent company of Olive Garden, surpassed Wall Street's earnings and revenue after reporting a fiscal fourth-quarter net... The exterior of an Olive Garden is seen on June 20, 2025 in Austin, Texas. Darden Restaurants, the parent company of Olive Garden, surpassed Wall Street's earnings and revenue after reporting a fiscal fourth-quarter net income of $303.8 million dollars. MoreWhat To Know Olive Garden is offering the same price of $13.99 for its Never Ending Pasta Bowl. The price hasn't changed since 2022, the Italian restaurant chain said in a new release. The deal goes live on Monday and includes unlimited pasta, plus endless soup or salad and breadsticks for the same price the fourth year in a row. However, there is one update to the deal this year. Guests will be able to choose the Spicy Three-Meat Sauce for their pasta, which features a blend of chili flakes, cherry peppers, red bell pepper, pepperoni, red wine, garlic and herbs and homemade meat sauce. The Never Ending Pasta Bowl will be available until November 16, allowing diners to mix and match up to 96 possible flavor combinations. This includes: Pastas: Fettuccine, Spaghetti, Angel Hair, Rigatoni Homemade Sauces: Spicy Three-Meat Sauce, Alfredo, Meat Sauce, Five Cheese Marinara, Traditional Marinara, Creamy Mushroom Endless toppings (add for $4.99): Crispy Chicken Fritta, Meatballs, Italian Sausage Olive Garden's eClub members gained early access to the deal on Monday, August 18. What People Are Saying Kevin Thompson, the CEO of 9i Capital Group and the host of the 9innings podcast, told Newsweek: "Whenever you see the phrase 'never ending' attached to a food item, it signals a calculated bet by the restaurant—with plenty of fine print attached. The real play isn't just the pasta; it's to get people in the door. Once customers are seated, restaurants aim to upsell drinks, appetizers, or desserts, which boost margins far more than the headline offer." Alex Beene, a financial literacy instructor for the University of Tennessee at Martin, told Newsweek: "Over the last few months, there have been a flurry of offers from restaurants trying to get customers to walk back through their doors after a few quarters declining foot traffic and sales. The issue, as with most consumer-based decisions, are inflationary pressures that have pushed dining prices higher over the last few years, and the result has largely been customers favoring dining at home to save money over going out. A never-ending pasta deal is yet another attempt to get customers' attention in the hopes they'll come back and start spending money with Olive Garden." What Happens Next As the restaurant industry continues to struggle with higher costs and shrinking margins, Thompson said the Never Ending Pasta Bowl deal is likely to get customers into the door, where they are likely to purchase other items as well. "Consumers, too, are feeling squeezed by inflation," Thompson said. "A 'never ending' pasta dish feels like a bargain, but making it a limited-time offer taps into scarcity, creating urgency and driving short-term traffic."


Business Wire
2 hours ago
- Business Wire
Vittori to Unveil First Hypercar in Miami on October 4, 2025
MIAMI--(BUSINESS WIRE)--Vittori, a new hypercar company, will unveil its first model on October 4, 2025 in Miami at a private, invite-only event. The running concept car was developed in collaboration with Pininfarina, the legendary Italian studio behind icons for Ferrari and Maserati. Vittori will unveil its first hypercar in Miami on Oct 4, 2025—developed with Pininfarina, with titanium 3D-printed components and a hybrid powertrain targeting 1,100 hp. Media invites: press@ Share The concept previews Vittori's engineering approach: AI-assisted design, lightweight construction with titanium 3D-printed components and advanced composites. Power comes from a hybrid system pairing a high-performance internal-combustion engine with electric motors and a high-voltage battery pack, targeting 1,100 horsepower. The car on display is a running concept; production specifications may change, and timing will be announced as development progresses. 'Partnering with Pininfarina lets us combine timeless design with modern manufacturing,' said Carlos Cruz, founder and CEO of Vittori. 'This concept shows the direction of our first production car—driver-focused, shaped by AI, and built with uncompromising materials.' Attendance at the Miami unveiling is by invitation only. Media and qualified buyers may request an invitation at press@ Images and b-roll will be available following the event. About Vittori Vittori is a high-performance automaker building next-generation hyper vehicles that blend AI-assisted design, additive manufacturing, and race-bred engineering. Learn more at Forward-Looking Statements This release contains forward-looking statements, including expected vehicle performance and development milestones. Actual results may differ due to engineering, certification, supply chain, and other factors. Vittori undertakes no obligation to update these statements. Trademarks Ferrari and Maserati are trademarks of their respective owners. Pininfarina is a trademark of Pininfarina S.p.A. Use here is for identification only and does not imply endorsement.